Please try another search
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company’s lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Name | Age | Since | Title |
---|---|---|---|
Joseph F. Lawler | 51 | 2020 | Founder & Chairman |
Jason M. Aryeh | 55 | 2021 | Independent Director |
Areta L. Kupchyk | 65 | 2021 | Independent Director |
Richard Cunningham | 52 | 2023 | CEO & Director |
Aron R. English | 41 | 2020 | Independent Director |
Kenneth S. Lin | 50 | 2021 | Lead Independent Director |
Bimal R. Shah | - | 2023 | Independent Director |
Andrew Monte | - | 2021 | Member of Scientific Advisory Board |
Arjun Chanmugam | - | 2021 | Member of Scientific Advisory Board |
Nathaniel Calloway | 41 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review